Wyeth Team Recognized by White House with Prestigious National Medal of Technology for PREVNAR Vaccine
Medal Recognizes Technological Innovation and Global Health Impact of PREVNAR Against Leading Vaccine-Preventable Cause of Death in Children Younger Than Five –
Madison, N.J.– Wyeth (NYSE:WYE) announced that a team of Wyeth scientists involved in the discovery, development and manufacture of PREVNAR®, Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein), will be awarded the 2005 National Medal of Technology today by President George W. Bush at a White House ceremony. The National Medal of Technology is the nation’s highest honor for technological achievement. PREVNAR is the first and only vaccine available to help protect infants and toddlers against invasive pneumococcal disease caused by vaccine serotypes.
The Medal is given to individuals, teams, and companies for outstanding contributions to the nation’s economic, environmental and social well-being, and recognizes those who have made lasting contributions to the United States’ standard of living and quality of life through technological innovation. The members of the Wyeth team honored by the White House are Drs. Ronald Eby, Velupillai Puvanesarajah, Dace Madore and Ms. Maya Koster.
“This award is a testament to these outstanding scientists and their colleagues as well as the pioneering science employed by Wyeth in the development of PREVNAR,” says Bernard Poussot, President, Chief Operating Officer and Vice Chairman, Wyeth. “This honor is also exemplary of the rich talent that is driving leading-edge research at Wyeth that will contribute to the improvement of global public health for years to come.”
Pneumococcal disease, a group of illnesses including bacteremia/ sepsis, meningitis, and bacteremic pneumonia, results in up to 1 million deaths each year in young children globally, and is the leading cause of vaccine-preventable death in children younger than five years of age.
The World Health Organization (WHO) announced in March 2007 its position to support the priority inclusion of pneumococcal conjugate vaccine (PCV-7) in national immunization programs worldwide.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.